Literature DB >> 24094379

Overview of severe Clostridium difficile infection.

Stephen R Eaton1, John E Mazuski.   

Abstract

Clostridium difficile is an anaerobic, spore-forming, gram-positive bacillus that can produce severe colitis resulting in death. There has been an overall increase in the incidence of Clostridium difficile-associated disease and, particularly, an increase in the more virulent forms of the disease. Treatment of severe C difficile infection includes management of severe sepsis and shock, pathogen-directed antibiotic therapy, and, in selected cases, surgical intervention. Ultimately, prevention is the key to limiting the devastating effects of this microorganism.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Clostridium difficile; Clostridium difficile colitis; Nosocomial infection; Pseudomembranous colitis

Mesh:

Substances:

Year:  2013        PMID: 24094379     DOI: 10.1016/j.ccc.2013.06.004

Source DB:  PubMed          Journal:  Crit Care Clin        ISSN: 0749-0704            Impact factor:   3.598


  4 in total

1.  Interleukin-22 regulates the complement system to promote resistance against pathobionts after pathogen-induced intestinal damage.

Authors:  Mizuho Hasegawa; Shoko Yada; Meng Zhen Liu; Nobuhiko Kamada; Raúl Muñoz-Planillo; Nhu Do; Gabriel Núñez; Naohiro Inohara
Journal:  Immunity       Date:  2014-10-16       Impact factor: 31.745

2.  A small-molecule antivirulence agent for treating Clostridium difficile infection.

Authors:  Kristina Oresic Bender; Megan Garland; Jessica A Ferreyra; Andrew J Hryckowian; Matthew A Child; Aaron W Puri; David E Solow-Cordero; Steven K Higginbottom; Ehud Segal; Niaz Banaei; Aimee Shen; Justin L Sonnenburg; Matthew Bogyo
Journal:  Sci Transl Med       Date:  2015-09-23       Impact factor: 17.956

3.  Effective Sequestration of Clostridium difficile Protein Toxins by Calcium Aluminosilicate.

Authors:  Joseph M Sturino; Karina Pokusaeva; Robert Carpenter
Journal:  Antimicrob Agents Chemother       Date:  2015-07-06       Impact factor: 5.191

4.  Cytotoxicity anticancer activities of anastrozole against breast, liver hepatocellular, and prostate cancer cells.

Authors:  Firas Hassan; Gamal A El-Hiti; Mays Abd-Allateef; Emad Yousif
Journal:  Saudi Med J       Date:  2017-04       Impact factor: 1.484

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.